title: Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report.
abstract: Treatment guidelines recommend omega-3 with Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) content not above 85% in patients with high plasma levels of triglycerides. Since the different up to date formulation of omega-3 available in commerce must be similar to clinical efficacy and safety, herein, we report the case a 52-year-old woman who presented clinical inefficacy using Olevia(®) omega-3 treatment. Clinical evaluation excluded the presence of intestinal or systemic diseases able to reduce the drug absorption. Switching the therapy from (Olevia(®)) to an equivalent omega-3 formulation (Esapent(®)), we documented a decrease in her plasma triglycerides levels. In order to evaluate a possible difference between these formulations we performed a single blind in vitro dissolution test using three pills for each formulation of omega-3 (Olevia(®), Esapent® and another one chosen between the several formulations available in commerce: DOC Generic(®)) that revealed a significant difference (>20%) in the dissolution time of three different omega- 3 commercially available drug formulation.
authors.affiliation: Department of Health Science, University of Catanzaro, Viale Europa, 88100 Catanzaro and Operative Unit of Clinical Pharmacology and pharmacovigilance, Azienda Ospedaliera MaterDomini, Via T Campanella 115, Catanzaro, Italy. gallelli@unicz.it.
authors.forename: Luca
authors.initials: L
authors.lastname: Gallelli
authors.forename: Andzelika
authors.initials: A
authors.lastname: Michniewicz
authors.forename: Roberta
authors.initials: R
authors.lastname: Stefanelli
authors.forename: Roberto
authors.initials: R
authors.lastname: Cannataro
authors.forename: Paola
authors.initials: P
authors.lastname: Longo
authors.forename: Mariarita
authors.initials: M
authors.lastname: Perri
authors.forename: Erika
authors.initials: E
authors.lastname: Cione
authors.forename: Maria C
authors.initials: MC
authors.lastname: Caroleo
mesh_terms: D004281:Docosahexaenoic Acids / Q000378:metabolism / Q000494:pharmacology; D004339:Drug Compounding; D057915:Drug Substitution / Q000379:methods*; D015118:Eicosapentaenoic Acid / Q000378:metabolism / Q000494:pharmacology; D015525:Fatty Acids, Omega-3 / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D016037:Single-Blind Method; D014280:Triglycerides / Q000037:antagonists & inhibitors* / Q000097:blood
chemical_list: C471808:Esapent; D015525:Fatty Acids, Omega-3; D014280:Triglycerides; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid